Cargando…

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs

SIMPLE SUMMARY: Somatic mutations in USP8 gene have been identified in 11–60% of patients with ACTH-secreting pituitary tumors. This study investigated the impact of USP8 mutations on corticotroph tumor cells responsiveness to the treatment with the somatostatin analog pasireotide. Although we found...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treppiedi, Donatella, Marra, Giusy, Di Muro, Genesio, Esposito, Emanuela, Barbieri, Anna Maria, Catalano, Rosa, Mangili, Federica, Bravi, Francesca, Locatelli, Marco, Lania, Andrea Gerardo, Ferrante, Emanuele, Indirli, Rita, Nozza, Emma, Arlati, Federico, Spada, Anna, Arosio, Maura, Mantovani, Giovanna, Peverelli, Erika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139692/ https://www.ncbi.nlm.nih.gov/pubmed/35626057 http://dx.doi.org/10.3390/cancers14102455

Ejemplares similares

Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant
por: Treppiedi, Donatella, et al.
Publicado: (2021)

A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation
por: Mangili, Federica, et al.
Publicado: (2021)

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022)

TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation
por: Treppiedi, Donatella, et al.
Publicado: (2022)

SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors
por: Mangili, Federica, et al.
Publicado: (2020)

Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation — High-Grade PitNET or PitNEC?
por: Saeger, Wolfgang, et al.
Publicado: (2021)

MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019)

Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior
por: Mantovani, Giovanna, et al.
Publicado: (2019)

SAT-566 Cofilin Is a Mediator of RET-Promoted Medullary Thyroid Carcinoma Cell Migration, Invasion and Proliferation
por: Peverelli, Erika, et al.
Publicado: (2019)

Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI
por: Amano, Taishi, et al.
Publicado: (2023)

SUN-213 The Role of Filamin A (FLNA) in the Regulation of Insulin-Like Growth Factor System in Adrenocortical Carcinomas
por: Peverelli, Erika, et al.
Publicado: (2020)

How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020
por: Trouillas, Jacqueline, et al.
Publicado: (2020)

Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET)
por: Gheorghe, Ana-Maria, et al.
Publicado: (2023)

PitNETs and the gut microbiota: potential connections, future directions
por: Nie, Ding, et al.
Publicado: (2023)

Expression and Clinical Significance of MDM2 in Non-Functioning PitNETs
por: Yao, Xiaohui, et al.
Publicado: (2023)

Expression and methylation status of LAMA2 are associated with the invasiveness of nonfunctioning PitNET
por: Wang, Ruo-Qiang, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art
por: Feola, Tiziana, et al.
Publicado: (2022)

The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
por: Dumitriu-Stan, Roxana-Ioana, et al.
Publicado: (2023)

PMON104 Sellar Gangliocytoma-Pituitary Neuroendocrine Tumor (PitNET) Presenting As Acromegaly
por: Aurora, John, et al.
Publicado: (2022)

Touch imprint cytology is useful for the intraoperative pathological diagnosis of PitNETs’ surgical margins
por: Tanabe, Noriaki, et al.
Publicado: (2023)

FRI370 Hyperthyroidism And Acromegaly In A Patient With A Mature Plurihormonal PIT1 Lineage PitNET/Adenoma
por: Slack, Daniel, et al.
Publicado: (2023)

Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways
por: Serioli, Simona, et al.
Publicado: (2023)

Endoscopic Endonasal Transplanum–Transtuberculum Approach for Pituitary Adenomas/PitNET: 25 Years of Experience
por: Carretta, Alessandro, et al.
Publicado: (2023)

Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET
por: Zhang, Qilin, et al.
Publicado: (2023)

Lactotroph PitNET/adenoma associated to granulomatous hypophysitis in a patient with Crohn's disease: A case report
por: Pietrantoni, Alberto, et al.
Publicado: (2022)

THU099 The Challenging Management Of Silent Corticotroph PitNET—From Very Aggressive To Mild Course Of Disease During Long Follow Up
por: Bogusławska, Anna, et al.
Publicado: (2023)

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
por: Mondin, Alessandro, et al.
Publicado: (2022)

Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line
por: Gentilin, E., et al.
Publicado: (2023)

Granulomatous mastitis (GM) in a young woman with a previous history of prolactin-secreting PitNET and actual normal prolactinemia
por: Boldrini, Cristiana
Publicado: (2022)

Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects
por: Vergeer, Rob A, et al.
Publicado: (2022)

Correction to: Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 2. Neoplasms other than PitNET and tumor-mimicking lesions
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Correction to: Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 2. Neoplasms other than PitNET and tumor-mimicking lesions
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sv3nouel6c2iq5a8ieudeo7tl8